After all the recent news about the PSA test, here's a genomics answer. The MD Anderson Cancer Center, demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells. The new prostate cancer test will be performed at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed. In some states this requires a physician's prescription. The test results are showing around a 93% accuracy rate. This is a gene-based prostate cancer test. One other note of interest is the process is free of outside intellectual property rights and thereby allows Health Discovery Corporation to fully patent protect the molecular diagnostic gene signatures.
This could serve to cause a bit more controversy on the PSA guidelines in the news this week. BD
Health Discovery Corporation today announced that HDC's new gene-based molecular diagnostic test for prostate cancer has now successfully completed it's Phase III double-blind clinical trial and is now ready for commercialization to be used by physicians on their patients at risk of having prostate cancer.
In a Press Release issued yesterday, Ron Andrews, CEO of Clarient stated "We are very impressed with the results from these validation studies, and I applaud the development teams from both Clarient and HDC for their diligent efforts in bringing this new test through the validation phase significantly ahead of schedule. The early results from these studies confirm our belief that this powerful genomics-based test may provide physicians with useful information to ensure that men with prostate cancer get a more accurate diagnosis sooner and minimize the need for unnecessary biopsies.
0 comments :
Post a Comment